Biodesix (BDSX) to Release Earnings on Thursday

Key Points

• Biodesix (BDSX) is set to release its Q2 2025 earnings on August 7th, with analysts predicting an earnings per share of ($0.07) and revenue of $18.47 million.
• The company has recently received multiple analyst downgrades, with price targets significantly reduced from $3.00 to as low as $1.50, although it maintains a consensus rating of "Moderate Buy."
• Biodesix shares have recently opened at $0.38 and have seen a 1-year price range between $0.17 and $2.04 amid reports of a negative net margin and return on equity.

Biodesix (NASDAQ:BDSX - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect Biodesix to post earnings of ($0.07) per share and revenue of $18.47 million for the quarter. Biodesix has set its FY 2025 guidance at EPS.

Biodesix (NASDAQ:BDSX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). Biodesix had a negative return on equity of 167.28% and a negative net margin of 54.28%. The firm had revenue of $17.96 million during the quarter, compared to analyst estimates of $19.50 million. On average, analysts expect Biodesix to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Biodesix Trading Up 3.3%

Shares of Biodesix stock traded up $0.01 on Friday, hitting $0.36. 469,857 shares of the company's stock traded hands, compared to its average volume of 1,092,553. The company has a fifty day moving average of $0.32 and a two-hundred day moving average of $0.58. Biodesix has a one year low of $0.17 and a one year high of $2.04. The company has a market capitalization of $53.23 million, a price-to-earnings ratio of -1.25 and a beta of 0.99. The company has a debt-to-equity ratio of 3.32, a current ratio of 2.22 and a quick ratio of 2.22.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Canaccord Genuity Group dropped their price target on Biodesix from $2.50 to $1.50 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Lake Street Capital cut their target price on shares of Biodesix from $3.00 to $2.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Scotiabank reduced their price target on shares of Biodesix from $3.00 to $2.00 and set a "sector outperform" rating for the company in a report on Wednesday, May 21st. William Blair reaffirmed a "market perform" rating on shares of Biodesix in a research note on Wednesday, May 14th. Finally, Craig Hallum dropped their price objective on shares of Biodesix from $3.00 to $1.50 and set a "buy" rating on the stock in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1.75.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.